The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System.
The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System.
复制标题
药物遗传学药物相互作用对90天再入院的贡献:来自现实世界医疗保健系统的初步结果。
DOI:
10.3390/jpm11121242
复制
发表时间:
2021-11-23
影响因子:
--
通讯作者:
Dunnenberger HM
中科院分区:
文献类型:
--
作者:
David SP;Singh L;Pruitt J;Hensing A;Hulick P;Meltzer DO;O'Donnell PH;Dunnenberger HM
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines exist for many medications commonly prescribed prior to hospital discharge, yet there are limited data regarding the contribution of gene-x-drug interactions to hospital readmissions. The present study evaluated the relationship between prescription of CPIC medications prescribed within 30 days of hospital admission and 90-day hospital readmission from 2010 to 2020 in a study population (N = 10,104) who underwent sequencing with a 14-gene pharmacogenetic panel. The presence of at least one pharmacogenetic indicator for a medication prescribed within 30 days of hospital admission was considered a gene-x-drug interaction. Multivariable logistic regression analyzed the association between one or more gene-x-drug interactions with 90-day readmission. There were 2211/2354 (93.9%) admitted patients who were prescribed at least one CPIC medication. Univariate analyses indicated that the presence of at least one identified gene-x-drug interaction increased the risk of 90-day readmission by more than 40% (OR = 1.42, 95% confidence interval (CI) 1.09–1.84) (p = 0.01). A multivariable model adjusting for age, race, sex, employment status, body mass index, and medical conditions slightly attenuated the effect (OR = 1.32, 95% CI 1.02–1.73) (p = 0.04). Our results suggest that the presence of one or more CPIC gene-x-drug interactions increases the risk of 90-day hospital readmission, even after adjustment for demographic and clinical risk factors.
登录
查看更多内容
影响因子:
3.7
作者:
Elliott LS;Henderson JC;Neradilek MB;Moyer NA;Ashcraft KC;Thirumaran RK
通讯作者:
Thirumaran RK
DOI:
10.1002/ajmg.c.31867
发表时间:
2021-03
期刊:
American journal of medical genetics. Part C, Seminars in medical genetics
影响因子:
--
作者:
Helseth DL Jr;Gulukota K;Miller N;Yang M;Werth T;Sabatini LM;Bouma M;Dunnenberger HM;Wake DT;Hulick PJ;Kaul KL;Khandekar JD
通讯作者:
Khandekar JD
影响因子:
1.9
作者:
Takahashi PY;Ryu E;Bielinski SJ;Hathcock M;Jenkins GD;Cerhan JR;Olson JE
通讯作者:
Olson JE
影响因子:
2.4
作者:
Brixner, D.;Biltaji, E.;Biskupiak, J.
通讯作者:
Biskupiak, J.
影响因子:
158.5
作者:
Zuckerman, Rachael B.;Sheingold, Steven H.;Epstein, Arnold M.
通讯作者:
Epstein, Arnold M.